ArticleThoracic cancer2023
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Open access · goldAbstract readConsensus Statement
In one paragraph
Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Observational
- Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC.Scientific reports · 2026Article
- Trastuzumab Deruxtecan as a Salvage Therapy after Disitamab Vedotin Failure in HER2 Altered Solid Tumors: A Preliminary Real-world Comparative Study.Pakistan journal of medical sciences · 2026Article
- Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.Discover oncology · 2025Article
- HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Efficacy of disitamab vedotin in non-small cell lung cancer withFrontiers in oncology · 2024Article
- Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review.Frontiers in oncology · 2024Article
- The diagnostic value ofFrontiers in medicine · 2024Article
- A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.Drug design, development and therapy · 2024Article
- Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects.Immunotherapy advances · 2024Review
- Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.Thoracic cancer · 2023Article
- Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
99 authors at 20 institutions in 2 countries.
Shirong ZhangTranslational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0001-9334-1637
Wenxian WangDepartment of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.ORCID 0000-0002-3047-4149
Chunwei XuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0002-9021-6731
Yongchang ZhangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.ORCID 0000-0002-6829-7176
Xiuyu CaiDepartment of VIP Inpatient, Sun Yet-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Qian WangDepartment of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Zhengbo SongDepartment of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.ORCID 0000-0002-4817-7775
Ziming LiDepartment of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jinpu YuDepartment of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Wenzhao ZhongGuangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.ORCID 0000-0002-8917-8635
Zhijie WangState Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jingjing LiuDepartment of Thoracic Cancer, Jilin Cancer Hospital, Changchun, China.
Anwen LiuDepartment of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wen LiKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Ping ZhanDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Hongbing LiuDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0003-1404-0647
Tangfeng LvDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Liyun MiaoDepartment of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0001-9586-3244
Lingfeng MinDepartment of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, China.
Gen LinDepartment of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China.ORCID 0000-0001-9411-5519
Long HuangDepartment of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China.ORCID 0000-0003-4925-5162
Jingping YuanDepartment of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
Zhansheng JiangDepartment of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID 0000-0002-5707-5148
Xingxiang PuDepartment of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Chuangzhou RaoDepartment of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Dongqing LvDepartment of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, China.
Zongyang YuDepartment of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, China.
Xiaoyan LiDepartment of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Chuanhao TangDepartment of Medical Oncology, Peking University International Hospital, Beijing, China.
Chengzhi ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, China.ORCID 0000-0003-0029-6879
Junping ZhangDepartment of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
Hui GuoDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Qian ChuDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rui MengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xuewen LiuDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
Jingxun WuDepartment of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen, China.
Jin ZhouDepartment of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu, China.
Zhengfei ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiwei PanDepartment of Cell Biology, College of Medicine, Jiaxing University, Jiaxing, China.
Xiaowei DongDepartment of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
Fei PangDepartment of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
Kai WangDepartment of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
Chao YaoDepartment of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
Guomin LinDepartment of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
Site LiDepartment of IVD Medical Marketing, 3D Medicines, Shanghai, China.
Zhi YangDepartment of IVD Medical Marketing, 3D Medicines, Shanghai, China.
Jiancheng LuoDepartment of Medical, Aiyi Technology, Beijing, China.
Hongtao JiaDepartment of Medical, Aiyi Technology, Beijing, China.
Xiuqing NieDepartment of Clinical Trial, Novocodex Biopharmaceutic, Shaoxing, China.
Liping WangDepartment of Oncology, Baotou Cancer Hospital, Baotou, China.
Youcai ZhuDepartment of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xiao HuZhejiang Key Laboratory of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Yanru XieDepartment of Oncology, Lishui Municipal Central Hospital, Lishui, China.
Xinqing LinState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, China.ORCID 0000-0001-9436-2229
Jing CaiDepartment of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China.ORCID 0000-0002-6792-4959
Yang XiaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.ORCID 0000-0003-2487-2244
Huijing FengDepartment of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
Lin WangDepartment of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
Yingying DuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0002-5149-4632
Wang YaoDepartment of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xuefei ShiDepartment of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China.
Xiaomin NiuDepartment of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Dongmei YuanDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Yanwen YaoDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jing KangGuangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.
Jiatao ZhangGuangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.
Chao ZhangGuangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.
Wenbin GaoDepartment of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
Jianhui HuangDepartment of Oncology, Lishui Municipal Central Hospital, Lishui, China.
Yinbin ZhangDepartment of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
Pingli SunDepartment of Pathology, The Second Hospital of Jilin University, Changchun, China.
Hong WangSenior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, China.
Mingxiang YeDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Dong WangDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Zhaofeng WangDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Bing WanDepartment of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Donglai LvDepartment of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, China.ORCID 0000-0002-3816-6319
Genhua YuDepartment of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou, China.
Lin ShiDepartment of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuanli XiaDepartment of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China.
Feng GaoDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaochen ZhangDepartment of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Tao XuDepartment of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wei ZhouInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
Haixia WangInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
Zhefeng LiuSenior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, China.
Nong YangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Lin WuDepartment of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Qiming WangDepartment of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Guansong WangInstitute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Zhuan HongDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
Jiandong WangDepartment of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Meiyu FangDepartment of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
Yong FangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Yiping ZhangDepartment of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
Yong SongDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0003-4979-4131
Shenglin MaDepartment of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
Wenfeng FangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yuanzhi LuDepartment of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, China.ORCID 0000-0003-2946-643X
Nanjing General Hospital of Nanjing Military Command · CNCentral South University · CNChinese Academy of Sciences · CNShanghai Medical Information Center · CNGuangdong Academy of Medical Sciences · CNJiaxing University · CNSun Yat-sen University · CNZhejiang Cancer Hospital · CNNanchang University · CNBaotou Central Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Guangzhou Medical University · CNFujian Medical University · CNiQIYI (China) · CNLishui Central Hospital · CNNanjing University of Chinese Medicine · CNShanghai Jiao Tong University · CNTianjin Medical University Cancer Institute and Hospital · CNWenzhou Medical University · CNAnhui Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2-targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2-altered NSCLC, focusing on the diagnosis and treatment strategies.
Indexed as
Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsEast Asian PeopleHumansIn Situ Hybridization, FluorescenceAntineoplastic Agentsantibody-drug conjugatenon-small cell lung cancerprecision medicinetargeted therapytyrosine receptor kinase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.